Practical guidelines for the therapy and monitoring of patients with systemic lupus erythematosus during a pandemic COVID-19

Clinical manifestations of COVID-19 coronavirus infection have similar clinical symptoms to systemic lupus erythematosus (SLE). This article provides a comparative diagnosis of these two diseases. Practical recommendations are also given to doctors for the management of patients with SLE varying degrees of activity in a pandemic coronavirus infection. Key words: systemic lupus erythematosus, COVID-19, treatment.

OCULAR MANIFESTATIONS IN SYSTEMIC LUPUS ERYTHAMATUSUS PATIENTS: A HOSPITAL BASED OBSERVATIONAL STUDY.

Objectives: This study was to evaluate the incidence and ocular manifestation in systemic lupus erythematosus (SLE) patients. Methods: A total of 50 cases with age group 15 to 50 years were enrolled. A detail history, clinical examinations and relevant investigations were performed to all cases. Patients who were diagnosed with systemic lupus erythamatusus (SLE) by using American Rheumatologic criteria with or without ocular features were included in this study. Results: Data was analysed by using simple statistical methods with the help of MS-office software. All data was tabulated and percentage was calculated. Conclusions: Females were commonly suffered with systemic lupus erythamatusus (SLE) and it was commonly seen in age 15-25 years. Episcleritis was the most common symptoms in SLE. Second most common symptoms were conjunctivitis and scleritis. Right eye was more affected than left eye. Most of the cases had ANA positive. Hence, ocular manifestation is the most common in SLE patients. Early diagnosis and prompt treatment may give light of hope for SLE patients. And more research is needed in order to determine which therapy will provide the best prevention and management in SLE patients. Key words: Systemic lupus erythamatusus (SLE), ocular manifestation, age group, ANA-positive.

Systemic Lupus Erythematosus

Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune illness characterized by autoantibodies directed at nuclear antigens that cause clinical and laboratory abnormalities, such as rash, arthritis, leukopenia and thrombocytopenia, alopecia, fever, nephritis, and neurologic disease. Most or all of the symptoms of acute lupus are attributable to immunologic attack on the affected organs. Many complications of long-term disease are attributable to both the disease and its treatment. Intense sun exposure, drug reactions, and infections are circumstances that induce flare; the aim of treatment is to induce remission. This chapter is divided into sections dealing with SLE’s definitions; epidemiology; pathogenesis; disease classification, diagnosis, and differential diagnosis; and treatment. This review contains 10 figures, 12 tables, and 97 references. Key Words: Systemic lupus erythematosus, Dermatomyositis, Sjögren syndrome, rheumatoid arthritis, systemic sclerosis, Discoid lupus erythematosus, truncal psoriasiform, annular polycyclic rash

Systemic Lupus Erythematosus

Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune illness characterized by autoantibodies directed at nuclear antigens that cause clinical and laboratory abnormalities, such as rash, arthritis, leukopenia and thrombocytopenia, alopecia, fever, nephritis, and neurologic disease. Most or all of the symptoms of acute lupus are attributable to immunologic attack on the affected organs. Many complications of long-term disease are attributable to both the disease and its treatment. Intense sun exposure, drug reactions, and infections are circumstances that induce flare; the aim of treatment is to induce remission. This chapter is divided into sections dealing with SLE’s definitions; epidemiology; pathogenesis; disease classification, diagnosis, and differential diagnosis; and treatment. This review contains 10 figures, 12 tables, and 97 references. Key Words: Systemic lupus erythematosus, Dermatomyositis, Sjögren syndrome, rheumatoid arthritis, systemic sclerosis, Discoid lupus erythematosus, truncal psoriasiform, annular polycyclic rash

Systemic Lupus Erythematosus

Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune illness characterized by autoantibodies directed at nuclear antigens that cause clinical and laboratory abnormalities, such as rash, arthritis, leukopenia and thrombocytopenia, alopecia, fever, nephritis, and neurologic disease. Most or all of the symptoms of acute lupus are attributable to immunologic attack on the affected organs. Many complications of long-term disease are attributable to both the disease and its treatment. Intense sun exposure, drug reactions, and infections are circumstances that induce flare; the aim of treatment is to induce remission. This chapter is divided into sections dealing with SLE’s definitions; epidemiology; pathogenesis; disease classification, diagnosis, and differential diagnosis; and treatment. This review contains 10 figures, 12 tables, and 97 references. Key Words: Systemic lupus erythematosus, Dermatomyositis, Sjögren syndrome, rheumatoid arthritis, systemic sclerosis, Discoid lupus erythematosus, truncal psoriasiform, annular polycyclic rash

THE RATE OF CLINICAL AND BIOLOGICAL MANIFESTATIONS IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS DIAGNOSED ACCORDING TO THE CRITERIA OF THE SLICC 2012

Aims: Determine the rate of clinical and biological manifestations in Systemic Lupus Erythematosus patients diagnosed according to the criteria of The Systemic Lupus International Collaborating Clinics SLICC 2012. Patients And Method: 55 patients were diagnosed with Systemic Lupus Erythematosus according to the criteria of the SLICC 2012, treated and followed up at Department of Nephrology and Rheumatology – Hue Central Hospital from March 2014 to April 2015. Results: The clinical manifestations rate: acute cutaneous lupus 58,2%; subacute cutaneous lupus 10,9%; chronic cutaneous lupus 10,9%; oral or nasal ulcers 18,2%; nonscarring alopecia 60%; synovitis 54,5%; serositis 32,7%, neurological damage 14,6%. The biological manifestations rate: hemolytic anemia 5,5%; leukopenia <4.000/mm3 25,5%; lymphopenia <1.000/mm3 49,1%; thrombocytopenia <100.000/mm3 16,4%; 24-hour urine protein representing >500 mg protein/24 hours 69,1%; ANA positivity 96,4%; anti-dsDNA antibody positivity 89,1%. Conclusion: In this study cohort, the clinical manifestations according to the criteria of the SLICC 2012 that have the highest rate are nonscarring alopecia, followed by acute cutaneous lupus and synovitis. The other clinical manifestations with lower rate are oral or nasal ulcers, neurological damage and chronic cutaneous lupus. Regarding biological manifestations, the presence of antinuclear antibodies, anti-dsDNA antibodies and renal damage with proteinuria >500mg/24 hours are the most prominent symptoms. Key words: Systemic Lupus Erythematosus, SLICC 2012

Distribution and Clinical Significance of Lupus Anticoagulant and Anticardiolipin Antibody with Systemic Lupus Erythematosus

Key words: Systemic lupus erythematosus; lupus anticoagulant; anticardiolipin antibody; thrombosis; neuropsychiatric manifestations; pregnancy loss; thrombocytopenia DOI: 10.3329/jcmcta.v20i1.4929 Journal of Chittagong Medical College Teachers' Association 2009: 20(1):16-22